Language:
  
[Sign in] [Register]   

EIAab logo

EIAab news detail, please contact eiaab@eiaab.com if you have any questions about online orders and payment.
Lipoxin A4 (LXA4) as a potential first trimester biochemical marker of intrauterine growth disorders
Update time:2016-12-12 22:27:44   【 Font: Large  Medium Small

Abstract
Objective: To evaluate first trimester maternal serum levels of lipoxin A4 (LXA4) in prediction of intrauterine fetal growth.

Methods: Study group of 185 patients in singleton pregnancy was divided into three subgroups according to neonatal birthweight: ≤10th percentile (SGA), 11–89th percentile (AGA) and ≥90 percentile (LGA).

Results: We observed decreased values of LXA4 concentrations, both in SGA- and LGA groups, when compared to AGA (68.91 ± 33.72 and 68.30 ± 23.49 versus 102.13 ± 121.90, respectively).

Conclusions: Lipoxin A4 may become an biochemical marker in the prediction of intrauterine fetal growth disturbances; however, more studies need to be undertaken to investigate LXA4’s role in pregnancy.

 

Cited products
Source:The Journal of Maternal-Fetal & Neonatal Medicine      by Lipa M, Bomba-Opoń D, Lipa J, et al.
Hot Genes
ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
Top Searches
Ubiquitin ELISA Asprosin Ubiquitin-protein ligase metalloproteinase TRAP1A Tumor necrosis vitamin d
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

Twitter